REGULATORY

83 ADR Reports from Patients Received in 4 Months after March Launch of New Reporting System: MHLW

November 20, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) said on November 18 that 83 adverse drug reaction (ADR) reports were received directly from patients by the end of July through a new ADR reporting system launched in late March. The…

To read the full story

Japan’s Direct Patient ADR Reporting System Now in Full Operation
March 27, 2019
Patient ADR Reporting System to Go into Full-Scale Operation by March-End
March 26, 2019
PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
PMDA to Introduce Direct ADR Reporting System for Patients on Trial Basis
January 20, 2012

REGULATORY

Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
Japan Health Minister Lauds Approval of iPSC-Based Therapies
March 9, 2026
Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
March 6, 2026
Forxiga Slapped with 36% Price Cut on PMP Return in FY2026 Revision
March 6, 2026
Japan Panel Clears Joenja, Dojolvi, Bayer MRI Contrast Agent
March 6, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…